Ra. Fisher et al., A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation, TRANSPLANT, 66(12), 1998, pp. 1616-1621
Background. The success of liver transplantation in this decade has become
the stimulus to extend the donor and recipient pool. Reducing early posttra
nsplant morbidity to maintain our success, as we expand our frontiers, has
led us to focus on balanced testing of multidrug immunosuppression regimens
.
Methods. A prospective trial in orthotopic liver transplantation using Myco
phenolate Mofetil and an identical steroid taper with randomization of pati
ents to Neoral (N) or Tacrolimus (FK) is the basis of this report. This was
an intent-to-treat study designed to compare the 6-month primary endpoints
of rejection and Infection and to compare the 6-month secondary endpoints
of liver function, renal function, bone marrow function, hypertension, and
serum cholesterol levels.
Results. Ninety-seven patients completed the 6-month follow-up period (N=49
, FK=48). The actual 6-month patient and graft survival rates were 98% and
94%, respectively. There was no difference in the number of patients with r
ejection episodes (N=11, FK=8) (P=0.61). There were 24 infections (3 cytome
galovirus) in the FK group and 30 infections (9 cytomegalovirus) in the N g
roup. The cholesterol levels at 6 months were not significantly different (
P=0.07) between the groups. The other secondary 6-month endpoints were not
significantly different, except total bilirubin, which was lower in the FK
arm (P=0.02).
Conclusions. The use of Mycophenolate Mofetil with N or FK and an identical
steroid taper after orthotopic liver transplantation is associated with ex
cellent graft and patient survival, and at 6 months, only 19% of the patien
ts experienced rejection, with a 48% overall infection rate.